Endocrine Abstracts

40-year-old female patient presented with acromegaly in 2008 (GH 61 (g/L, IGF-1 774 ng/ml PRL 1500 mU/L). Macro-adenoma invading the right cavernous sinus was found on MRI and she underwent two pituitary surgeries revealing sparsely granulated GH adenoma with scattered PRL cells, low Ki 67 and negative p53 immuno-staining. Her second cousin was treated for macro prolactinoma. Both patients tested negative for germline mutations in the AIP and menin genes. Treatment with somato...

Background: Increased life expectancy and wider availability of neuroimaging lead to increase in diagnosis of acromegaly in elderly patients, after the age of 70. Delay in diagnosis is attributable to milder symptomatology, higher prevalence of comorbidities and symptoms overlapping with normal aging process.Objective: To investigate clinical characteristics, presenting symptoms, comorbidities and treatment modalities of acromegaly in patients diagnosed ...

Background: A subset of patients with prolactinomas does not respond satisfactorily to first-line medical therapy with dopamine agonists (DA). DA resistance is defined as failure to normalize prolactin (PRL) levels and/or to achieve ≥50% reduction in maximal tumor diameter under maximally tolerated doses (or a weekly cabergoline dose of ≥3mg). The predictive factors for DA resistance are male gender and tumor invasiveness.Aim: To characterize...

Introduction: Considering the mitogenic potential of GH and IGF1, the safety profile of growth hormone therapy since the beginning of its use has been debated. From that point of view, adolescents in transition to adulthood who were treated in childhood for endocranial tumors or malignancies require special caution.Patients and Methods: In a monocentric, observational, retrospective cross-sectional study spanning 18 years, we analyzed 251 childhood onset...